Scott Weerasuriya

Scott Weerasuriya

Auto-generated profile, based on publicly available information

Scott Weerasuriya

Department of Anaesthesia, Queen Elizabeth Hospital, Lewisham & Greenwich NHS Trust, United Kingdom

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

23 July 2024 in Anaesthesiology Intensive Therapy
Verified
Journal Article
Open access
SWScott Weerasuriya
Scott Weerasuriya
DSDale Seddon
Dale Seddon
VSVishal Salota
Vishal Salota

11 October 2021 in Case Reports in Gastroenterology
Verified
Journal Article
Open access
PDF file
SWScott Weerasuriya
Scott Weerasuriya
KPKieran Palmer
Kieran Palmer
SGStephen Gregory
Stephen Gregory
BWBenjamin C. Whitelaw
Benjamin C. Whitelaw
EGElisa Gonzalez
Elisa Gonzalez
RSRajaventhan Srirajaskanthan
Rajaventhan Srirajaskanthan
Pancreatic neuroendocrine tumours can have varied and complex presentations. Whilst hormone hypersecretion often induces characteristic clinical syndromes, non-specific symptoms may arise due to localized tumour effects. Malignant invasion of local vasculature is an increasingly recognized complication of these neoplasms and can be associated with significant morbidity. Herein, we present the case of a 47-year-old male with a recurrence of a pancreatic neuroendocrine tumour who presented with unusual upper gastrointestinal bleeding. The tumour had recurred within the superior mesenteric vein, replacing the vessel and invading its branches. This resulted in porto-mesenteric hypertension and the formation of bleeding mesenteric varices. The patient subsequently developed progressive metabolic disturbances and was diagnosed with ectopic Cushing’s syndrome, despite his primary tumour having been non-functional. This case demonstrates not only a rare pattern of tumour recurrence but also the potential for pancreatic neuroendocrine tumours to de-differentiate and change from non-functional to hormone secreting, a phenomenon which may complicate diagnosis and management.

27 February 2023 in Acute and Critical Care
Verified
Journal Article
Open access
SWScott Weerasuriya
Scott Weerasuriya
SVSavvas Vlachos
Savvas Vlachos
ABAhmed Bobo
Ahmed Bobo
NJNamitha Birur Jayaprabhu
Namitha Birur Jayaprabhu
LMLauren Matthews
Lauren Matthews
VMVictoria Metaxa
Victoria Metaxa
It can be challenging for clinicians to predict which patients with respiratory failure secondary to coronavirus disease 2019 (COVID-19) will fail on high-flow nasal cannula (HFNC) oxygen and require escalation of therapy. This study set out to evaluate the association between the respiratory rate-oxygenation index (ROX) and HFNC failure in such patients and to assess whether ROX trajectory correlates with treatment failure. This was a single-centre, retrospective, observational study of patients with COVID-19 requiring HFNC, conducted over a 3-month period. ROX was calculated as "pulse-oximetry oxygen saturation (SpO2) over the fractional inspired oxygen concentration (FiO2)/respiratory rate" for each patient at 2, 4, and 12 hours from starting HFNC. HFNC failure was defined as escalation to continuous positive airway pressure ventilation or invasive mechanical ventilation (IMV). Time-to-event analyses were performed to account for the longitudinal data set and time-dependent variables. We included 146 patients. Ninety-three (63.7%) experienced HFNC failure, with 53 (36.3%) requiring IMV. Higher ROX values were associated with a lower subhazard of HFNC failure on time-to-HFNC failure analysis (subhazard ratio, 0.29; 95% confidence interval [CI], 0.18-0.46; P<0.001). This remained true after controlling for informative censoring. Median ROX values changed differentially over time, increasing in the HFNC success group (0.06 per hour; 95% CI, 0.05-0.08; P<0.001) but not in the HFNC failure group (0.004 per hour; 95% CI, -0.05 to 0.08; P=0.890). A higher ROX is associated with a lower risk of HFNC failure. Monitoring ROX trajectory over time may help identify patients at risk of treatment failure. This has potential clinical applications; however, future prospective studies are required.

17 October 2026 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
JDJames Durrand
James Durrand
BHBo Hou
Bo Hou
AHAdam Hunt
Adam Hunt
ELEimear Lusby
Eimear Lusby
EWEleanor Warwick
Eleanor Warwick
PCPQIP collaborative
PQIP collaborative